Kunpeng Wu

Kunpeng Wu

Auto-generated profile, based on publicly available information

Kunpeng Wu

Department of Oncology, Heyuan People's Hospital, Guangdong Provincial People's Hospital Heyuan Hospital, Heyuan, Guangdong 517000, China; Heyuan Key Laboratory of Molecular Diagnosis & Disease Prevention and Treatment, Doctors Station of Guangdong Province, Heyuan People's Hospital, Heyuan, Guangdong 517000, China

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 January 2019 in Journal of Cellular Biochemistry
Verified
Journal Article
Closed access
PDF file
ZLZhuoxing Liu
Zhuoxing Liu
KWKunpeng Wu
Kunpeng Wu
JWJian Wu
Jian Wu
DTDan Tian
Dan Tian
YCYue Chen
Yue Chen
AWAibing Wu
Aibing Wu

5 September 2025 in British Journal of Cancer
Verified
Journal Article
Closed access
PDF file
KWKun-Peng Wu
Kun-Peng Wu
XLXu-Qiang Luo
Xu-Qiang Luo
QLQing-Qing Li
Qing-Qing Li
HYHong-Cheng Yang
Hong-Cheng Yang
MJMei-Chen Ji
Mei-Chen Ji
YLYang-Si Li
Yang-Si Li

21 April 2026 in SSRN Electronic Journal
Verified
Preprint
Open access
KWKunpeng Wu
Kunpeng Wu
XLXu-Qiang Luo
Xu-Qiang Luo
PTPeixin Tan
Peixin Tan
HYHong-Cheng Yang
Hong-Cheng Yang
MJMeichen Ji
Meichen Ji
DTDan Tian
Dan Tian
Background: Nasopharyngeal carcinoma (NPC), endemic to Southern China and Southeast Asia, presents significant clinical challenges. Immune checkpoint inhibitors (ICIs) have transformed NPC treatment but carry risks of immune-related adverse events (irAEs). Existing meta-analyses lack NPC-specific data, hindering targeted safety guidance.Methods: This systematic review and meta-analysis, registered with PROSPERO (CRD420251003062), followed PRISMA guidelines. We searched PubMed, Embase, and Web of Science up to March 31, 2025, including all registered clinical trials of ICIs in NPC patients reporting irAEs. Meta-analysis was employed to calculate all grade and ≥3 grade irAE incidence rates. Pooled analysis was applied to delineate the cumulative number of cases for all kinds of irAE and the causes of death attributed to irAEs in patients with NPC.Findings: A total of 27 clinical trials were included in the meta-analysis. The pooled incidence of all-grade irAEs in 2296 patients was 69.1% (95% CI: 50.4%-80.7%), and that of grade 3 or higher irAEs in 2459 patients was 8.1% (95% CI: 6.1%-10.6%). Subgroup analyses revealed that there were no significant differences in the incidence of irAEs based on disease stages, lines of treatment, and combination treatment strategies. The main types of all-grade irAEs with an incidence rate greater than 1% are as follows: hypothyroidism (22.4%), rash (10.7%), pruritus (3.6%), increased aspartate aminotransferase (1.9%), increased alanine aminotransferase (1.8%), fatigue (1.6%), anemia (1.6%), pneumonia (1.5%), and hyperthyroidism (1.0%). A total of 17 patients died due to irAEs. Among these, sepsis was the most common cause of death, followed by pneumonitis.Interpretation: This meta-analysis provides a comprehensive overview of irAEs in NPC patients treated with ICIs. These NPC-specific data emphasize the importance of vigilant monitoring for endocrine, cutaneous, and severe pulmonary or infectious complications to balance the efficacy and safety of ICIs.

6 February 2026 in Med
Verified
Journal Article
Closed access
KWKun-Peng Wu
Kun-Peng Wu
XLXu-Qiang Luo
Xu-Qiang Luo
PTPei-Xin Tan
Pei-Xin Tan
QLQing-Qing Li
Qing-Qing Li
HYHong-Cheng Yang
Hong-Cheng Yang
YLYang-Si Li
Yang-Si Li

16 March 2026 in SSRN Electronic Journal
Verified
Preprint
Open access
MWMin-Yu Wen
Min-Yu Wen
BLBin Li
Bin Li
ZDZhe Dong
Zhe Dong
WLWen-Fei Li
Wen-Fei Li
KWKunpeng Wu
Kunpeng Wu
CXCheng Xu
Cheng Xu
Purpose: To investigate the optimal replanning timing for adaptive radiotherapy and the role of programmed cell death protein-1 (PD-1) blockade in nasopharyngeal carcinoma (NPC).Patients and Methods: In this retrospective, longitudinal time-series, cohort study, patients with NPC underwent intensity-modulated radiotherapy with daily or weekly cone beam computed tomography (CBCT) in China between 2020 and 2023. CBCT image-based delineations were conducted to evaluate dynamic changes of the primary tumor, lymph nodes, and parotid glands. Parotid function was assessed via the European Organization for Research and Treatment of Cancer questionnaire. Between-group comparisons were performed using Two-way Repeated-Measures ANCOVA. Kaplan-Meier analysis and Cox regression were used to compare survival outcomes.Results: Analysis of 404 eligible patients (31·8% women) revealed two distinct patterns of rapid and slow regression for primary tumors (25,580 images; least‑squares mean difference, -0·929cm2; p<0·001) and lymph nodes (4,041 images; least‑squares mean difference, -0·083cm2; p<0·001). Parotid glands were more susceptible to shrinkage in the rapid regression group than in the slow regression group, with an increased risk of dry mouth (p=0·033) and sticky saliva (p=0·029). The primary tumor showed sustained significant reduction in the rapid regression group until the 21st fractions, before the mean parotid dose reached the restricted threshold of 25 Gy. Concurrent PD-1 blockade correlated with slower regression of the primary tumor (p=0·035) and lymph nodes (p=0·005). Patients with primary tumor regression by the 6th fraction had significantly improved event-free survival (HR, 0·37; 95% CI, 0·15 to 0·95; p=0·031) and overall survival (HR, 0·24; 95% CI, 0·05 to 0·98; p=0·043).Conclusions: The 21st fraction was proposed to trigger radiotherapy replanning for rapidly regressing NPC. Compared with concurrent chemoradiotherapy, additional PD-1 blockade was associated with poorer tumor regression.